DW16011 combination treatment improves acute bronchitis

An oral fixed-dose combination syrup composed of DW16011 and Pelargonium sidoides improved symptoms of acute bronchitis better than DW16011 or P. sidoides alone, according to study results.

In this randomized, double-blind, placebo controlled, multi-center trial, 204 patients with acute bronchitis were randomized 1:1:1 to receive DW1601 (n = 67), DW16011 (n = 70), or P. sidoides (n = 64) for 1 week.

From baseline to day 4, there was a significantly greater decrease of total bronchitis severity score in the DW1601 group than in the DW16011 group or P. sidoides group.

Patients in the DW1601 group had significantly more improved BSS total score on day 7 and BSS cough and sputum component scores at days 4 and 7 compared with the other groups.

Patients treated with DW1601 also had higher rates of response and satisfaction. There were no significant adverse events observed in the DW1601 group.

Reference
Lee YS, Lim SY, Min KH, et al. The efficacy and safety of DW1601 in patients with acute bronchitis: a multi-center, randomized, double-blind, phase III clinical trial. Korean J Intern Med. 2022;doi: 10.3904/kjim.2022.104. Epub ahead of print. PMID: 36153858.